Wechselwirkungen · Avamys
AVAMYS 27.5 micrograms/spray, nasal spray suspension · Abschnitt 4.5 · PDF-Seite 4
HOS-117580 · Präparat HOS-094649
Caution is recommended when co-administering fluticasone furoate with potent CYP3A inhibitors including cobicistat-containing products as an increase in the risk of systemic side effects is expected. Co- administration should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side effects, in which case patients should be monitored for systemic corticosteroid side effects. In a drug interaction study of intranasal fluticasone furoate with the potent CYP3A4 inhibitor ketoconazole there were more subjects with measurable fluticasone furoate concentrations in the ketoconazole group (6 of the 20 subjects) compared to placebo (1 out of 20 subjects). This small increase in exposure did not result in a statistically significant difference in 24 hour serum cortisol levels between the two groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-27T16:10:00Z · SHA-256 c89a2ed7d1e1a06b5aa0c412d89c867a0a50f9db93f01a9594c0b1433f4200fc · Passage a6bce8af394b381bd71e4bd17ab8e2c1cc497b2d4370f2307de55f5a05e86df5 · Zeichen 373–1206 im Abschnitt